Drug startups coalesce around condensates

Elie Dolgin • February 9, 2021

Once a neglected biological phenomenon, condensates are attracting interest from small companies and large pharmas.

Three startups debuted in late 2020, all aiming to treat disease by manipulating the physiochemical and regulatory processes in cells that drive membrane-less hubs associated with disease pathogenesis. The field’s frontrunner, Dewpoint Therapeutics, also signed a major research pact last month with Pfizer — Dewpoint’s third such deal with a large pharma partner since the company’s inception two years ago.


Continue reading at Nature Biotechnology.

Clock face, DNA strand and assortment of animals: dolphins, deer, bears, whale, baboon
By Elie Dolgin September 22, 2025
Molecular signatures of aging are changing how conservationists assess population health, resilience and risk.
Yellow rings of DNA amidst white chromosomes
By Elie Dolgin September 11, 2025
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.